Viatris Slashes Full-Year Revenue Guidance By $800m
Strengthening US Dollar Continues To Be Significant Headwind
Executive Summary
Viatris is committing to earlier EBITDA and free cash flow targets for 2022, although it now expects to lose a chunk of revenues for the full year amid severe and sustained foreign currency exposure.
You may also be interested in...
Viatris: Complex Injectable Pipeline Opportunities Worth At Least $1bn
A generic version of Novo Nordisk’s GLP-1 receptor agonist Wegovy (semaglutide) treatment for obesity is among seven complex generic injectables for which Viatris is claiming first-to-file status, as it looks to return to growth in 2024 and beyond.
Stock Watch: Will Static Pricing And Rising Inflation Compress Pharmaceutical Margins?
Generic pharmaceutical margins are notoriously thin while pricing is limited by intense competition. What happens to margins when raw material and energy pressures rise?
Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode
Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of generic Asacol revenues even as Zydus expects volume growth and new launches to help grow its US business.